Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis

<p><strong>Objectives</strong> To examine which composite measures are most sensitive to change when measuring psoriatic arthritis (PsA) disease activity, analyses compared the responsiveness of composite measures used in a 48-week randomized, controlled trial of MTX and etanercep...

Bibliografski detalji
Glavni autori:	Coates, L, Merola, JF, Mease, PJ, Ogdie, A, Gladman, DD, Strand, V, van Mens, L J.J., Liu, L, Yen, PK, Collier, DH, Kricorian, G, Chung, JB, Helliwell, PS
Format:	Journal article
Jezik:	English
Izdano:	Oxford University Press 2020

Slični predmeti

A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combinstion for treating psoriatic arthritis: A comparison of the composite measures used to evaluate disease activity
od: Mease, PJ, i dr.
Izdano: (2019)

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)
od: Mease, P, i dr.
Izdano: (2018)

Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination
od: Vibeke Strand, i dr.
Izdano: (2021-04-01)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
od: Helliwell, PS, i dr.
Izdano: (2022)

Methotrexate in psoriasis and psoriatic arthritis
od: Coates, L, i dr.
Izdano: (2020)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
od: Ogdie, A, i dr.
Izdano: (2023)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
od: Atul Deodhar, i dr.
Izdano: (2022-07-01)

Classification and outcome measures for psoriatic arthritis
od: Leung, Y, i dr.
Izdano: (2018)

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance
od: Nash, P, i dr.
Izdano: (2020)

Initiating evaluation of composite outcome measures for psoriatic arthritis: 2022 updates from the GRAPPA-OMERACT Working Group
od: Leung, Y-Y, i dr.
Izdano: (2023)

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies
od: Tillett, W, i dr.
Izdano: (2017)

Measuring outcomes in psoriatic arthritis
od: Ogdie, A, i dr.
Izdano: (2020)

Real‐World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
od: Philip J. Mease, i dr.
Izdano: (2023-08-01)

Classification and Outcome Measures for Psoriatic Arthritis
od: Ying Ying Leung, i dr.
Izdano: (2018-09-01)

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
od: Alexis Ogdie, i dr.
Izdano: (2023-05-01)

Outcomes of the 2019 GRAPPA workshop on continuous composite indices for the assessment of psoriatic arthritis and membership: Recommended next steps
od: Tillett, W, i dr.
Izdano: (2020)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
od: Gladman, DD, i dr.
Izdano: (2022)

Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores
od: Weinstein, SM, i dr.
Izdano: (2021)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
od: Coates, L, i dr.
Izdano: (2021)

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
od: Coates, LC, i dr.
Izdano: (2022)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
od: Gladman, DD, i dr.
Izdano: (2018)

Appraisal of candidate instruments for assessment of the physical function domain in patients with psoriatic arthritis
od: Leung, YY, i dr.
Izdano: (2020)

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology consensus‐based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis
od: Coates, L, i dr.
Izdano: (2017)

Should methotrexate have any place in the treatment of psoriatic arthritis?
od: Ye, W, i dr.
Izdano: (2019)

Treatment to target in psoriatic arthritis with apremilast: probability of achieving targets and comprehensive control of disease manifestations
od: Mease, PJ, i dr.
Izdano: (2020)

Incidence and Risk Factors of Hepatic Fibrosis in Psoriatic Patients Receiving Methotrexate with Concomitant Acitretin Therapy and Methotrexate Monotherapy
od: Rattanakaemakorn P, i dr.
Izdano: (2021-05-01)

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
od: Coates, L, i dr.
Izdano: (2019)

Etanercept (Enbrel) in the treatment of psoriatic arthritis
od: T V Korotaeva
Izdano: (2009-12-01)

Considerations for the definition of remission criteria in psoriatic arthritis
od: Mease, P, i dr.
Izdano: (2017)

Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA)
od: Michelle L. M. Mulder, i dr.
Izdano: (2020-02-01)

Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review
od: Leung, Y-Y, i dr.
Izdano: (2020)

The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
od: Strand, V, i dr.
Izdano: (2022)

THE DIAGNOSIS OF PSORIATIC ARTHRITIS
od: P.S. Helliwell
Izdano: (2011-09-01)

Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial
od: Henriëtte M. Y. de Jong, i dr.
Izdano: (2019-09-01)

Test-retest reliability for HAQ-DI and SF-36 PF for the measurement of physical function in psoriatic arthritis
od: Leung, YY, i dr.
Izdano: (2021)

Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial
od: Gossec, L, i dr.
Izdano: (2024)

Psoriatic arthritis: prospects for the future
od: Hackett, S, i dr.
Izdano: (2022)

The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 annual meeting: report and plan for completing the core outcome measurement set
od: Leung, Y, i dr.
Izdano: (2019)

BIOLOGIC THERAPY OF PSORIATIC ARTHRITIS
od: D.D. Gladman
Izdano: (2011-09-01)

Effect of Monotherapy with Methotrexate, Etanercept and their Combination on the Quality of Life in Children with Early and Late Juvenile Idiopathic Arthritis: A Prospective Study
od: Anna N. Fetisova, i dr.
Izdano: (2018-10-01)